Lou Sehl, Ph.D.

Dr. Lou Sehl has more than 30 years of experience in the biotechnology, pharmaceutical, and medical device industries, with a consistent track record of success moving projects through all phases of development. Prior to Evommune, he was Vice President of Manufacturing and Technical Operations at MyoKardia, acquired by BMS in late 2020, where he led CMC efforts for multiple clinical development programs, including managing CMC relationships with Sanofi during a four-year partnership. His efforts were instrumental in the successful NDA filing for CAMZYOS™ (mavacamten). Prior to MyoKardia, Lou served as Vice President of Product Development at Medicines360, where he was responsible for drug, device, and nonclinical development and supply chain activities. He has also held leadership positions in R&D at Proteolix, Cohesion Technologies, COR Therapeutics, and Genentech, and has contributed to 5 IND, 3 IDE, 3 PMA, and 3 NDA filings. He earned a PhD in biochemistry from the University of Notre Dame and a BA in chemistry from Carthage College.